Innovative Drugs to Restore Neurological Function
Jun 24, 2013 by bioadmin
Cambridge, MA, September 25, 2013 – BioAxone BioSciences Inc. Announces Publication of Cethrin™ Spinal Cord Injury Clinical...
Dr. Lisa McKerracher, CEO of BioAxone, participated on a panel at the CEO NY Conference, Nov. 12-13 in New York City. This...
Posted by bioadmin on Jan 2, 2012
BioAxone BioSciences Inc. is focused on the development of innovative drugs to restore neurological function and improve quality of life for patients with spinal cord injury and neurotrauma.
Our lead product, Cethrin™ is a proprietary biological drug, and our clinical Phase 2b program is paving the way as the most advanced treatment for spinal cord injury.
Phase II clinical results show enormous promise of Cethrin to promote meaningful and substantial recovery and to safely advance the road to repair.
© 2013 BioAxone Biosciences. All Rights Reserved.